EOC Gears To Evolve Into Integrated Oncology Company
Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.
You may also be interested in...
Eddingpharm, a Chinese specialty pharmaceutical company, is strengthening its international collaborations to bring more innovative products into the China market. The company has recently signed an agreement with Spain’s Faes Farma to establish a joint venture and commercialize Faes’ products in China.
Ablynx has signed a deal with Chinese company Eddingpharm for certain Asian rights to its rheumatoid arthritis drug ozoralizumab, marking a fresh start for the anti-TNF nanobody after Pfizer backed out of a global deal in 2011.
In its latest deal, Eddingpharm continues its march forward from a third-party promotional partner for companies like GSK, to a China-based specialty pharma. After in-licensing a string of compounds last year, it has now added three more from ACT Biotech.